A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers

Trial Profile

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Athenex
  • Most Recent Events

    • 14 Aug 2017 According to an Athenex media release, the company submitted Investigational New Drug (IND) Application of Oraxol to Chinese FDA in July and commenced this trial.The IND application has been accepted by the Chinese FDA for review.
    • 19 Jul 2017 According to an Athenex media release, first patient has been dosed.
    • 12 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top